Compounded Semaglutide vs Brand Wegovy
GLP-1 Drug Access and Cost
$1,349/month list price
Wegovy's list price drove millions of patients toward compounded alternatives at $200-500/month. The FDA ended the semaglutide shortage designation in February 2025, restricting compounding access.
FDA Drug Shortage Resolution, February 2025
FDA Drug Shortage Resolution, February 2025
View as imageSemaglutide is a 31-amino-acid GLP-1 receptor agonist peptide that has generated some of the strongest weight loss and cardiovascular data of any drug in the past decade. Wegovy (semaglutide 2.4 mg weekly injection) is the FDA-approved version for chronic weight management, backed by the STEP trial program. Compounded semaglutide refers to versions produced by compounding pharmacies, typically at a fraction of the brand price, using semaglutide salt forms rather than the base peptide. For broader context on the economics of GLP-1 drugs, see our cost-effectiveness analysis.
These are not the same product. The differences span chemistry, manufacturing, testing, delivery, and regulatory status. This article examines each difference in detail, including the regulatory landscape as of early 2026.
Key Takeaways
- Brand Wegovy uses semaglutide base; compounded versions typically use semaglutide acetate or sodium salt, which have different molecular weights and have not been evaluated for safety or efficacy by the FDA
- Wegovy's clinical data comes from the SUSTAIN and STEP trial programs: over 15,000 patients across multiple Phase 3 RCTs demonstrating 14.9% average weight loss at 68 weeks
- Compounded semaglutide has zero published clinical trial data for safety, efficacy, or bioequivalence
- The FDA removed semaglutide from its drug shortage list on February 21, 2025, triggering compounding deadlines: April 22, 2025 for 503A pharmacies, May 22, 2025 for 503B outsourcing facilities
- Compounded semaglutide is packaged in multi-dose vials requiring patient-drawn doses, increasing the risk of dosing errors and contamination compared to Wegovy's prefilled autoinjector
- A pooled analysis of SUSTAIN 6 and PIONEER 6 trials found semaglutide (brand) reduced major adverse cardiovascular events by 24% (Husain et al., Diabetes, Obesity and Metabolism, 2020)
The Chemical Difference: Base vs. Salt Forms
The distinction between semaglutide base and semaglutide salts is not trivial. Brand Wegovy and Ozempic contain semaglutide in its base form, a specific 31-amino-acid peptide with a C-18 fatty acid side chain that enables albumin binding and extends its half-life to approximately 7 days.
Compounding pharmacies have used semaglutide acetate and semaglutide sodium, which are salt forms of the peptide. These salt forms have different molecular weights than semaglutide base. Semaglutide acetate, for example, includes an acetate counterion that adds mass to each molecule. If a dose is calculated based on the total weight of semaglutide acetate rather than the active semaglutide content, patients could receive less active peptide than intended. The FDA has flagged this as a source of dosing errors.
The salt forms have not been studied in clinical trials. The SUSTAIN and STEP programs that established semaglutide's safety and efficacy profile used only the base form. Whether the salt forms produce equivalent pharmacokinetics (absorption, distribution, peak levels, duration) has not been determined. The assumption that they are interchangeable is exactly that: an assumption without supporting data.
What the Brand Clinical Data Actually Shows
Wegovy's approval rests on one of the most extensive clinical trial programs in obesity medicine.
The SUSTAIN Trials
The SUSTAIN program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) comprised seven Phase 3 trials establishing semaglutide's glycemic and cardiovascular profile. SUSTAIN 6, a 104-week cardiovascular outcomes trial in 3,297 patients with type 2 diabetes, demonstrated that semaglutide reduced major adverse cardiovascular events (MACE) by 26% compared to placebo.[1]
A comparative review of the SUSTAIN trials confirmed semaglutide's superiority over other GLP-1 receptor agonists for both HbA1c reduction and weight loss, with a consistent safety profile across all seven trials.[2]
Pooled Cardiovascular Analysis
A pooled analysis of individual patient data from SUSTAIN 6 (injectable) and PIONEER 6 (oral semaglutide) encompassing 6,480 patients found semaglutide reduced MACE by 24% overall (HR 0.76, 95% CI 0.62-0.92) and stroke by 35%.[3] These cardiovascular benefits are a key part of semaglutide's value proposition that is entirely unproven for compounded versions.
Meta-Analysis Confirmation
A systematic review and meta-analysis of all randomized controlled trials confirmed semaglutide's efficacy and safety for type 2 diabetes, with consistent HbA1c reductions of 1.0-1.8% and weight loss of 3.5-6.5 kg across dosing levels.[4]
None of this data applies to compounded semaglutide. Compounded versions have not been tested in any published clinical trial for weight loss, diabetes, cardiovascular outcomes, or any other endpoint. For a detailed look at the weight loss evidence specifically, see our article on semaglutide for weight loss without diabetes.
Manufacturing and Quality Differences
FDA-Regulated Manufacturing (Wegovy)
Novo Nordisk manufactures Wegovy under current Good Manufacturing Practices (cGMP), the FDA's stringent requirements for pharmaceutical production. This includes validated manufacturing processes, batch-by-batch potency and purity testing, stability testing under various storage conditions, endotoxin testing, sterility assurance, and defined acceptance criteria for every measurable quality attribute. Each batch of Wegovy undergoes the same testing before release.
Compounding Pharmacy Production
Compounding pharmacies operate under different regulatory frameworks depending on their classification.
503A pharmacies (traditional compounding pharmacies) produce medications pursuant to individual patient prescriptions. They are regulated primarily by state boards of pharmacy, not the FDA. They are not required to follow cGMP, do not need to report adverse events to the FDA, and their products are not subject to FDA pre-market review.
503B outsourcing facilities voluntarily register with the FDA and can produce compounded medications without individual prescriptions. They must follow cGMP and report adverse events, but their products still do not undergo the safety and efficacy review required for FDA-approved drugs.
The practical consequence: compounded semaglutide may vary in potency, purity, and sterility between batches and between pharmacies. The FDA has identified instances where compounders used incorrect salt forms, had dosing calculation errors, or produced products with contamination.
Delivery Device
Wegovy comes in a prefilled, single-use autoinjector pen with preset doses (0.25, 0.5, 1.0, 1.7, and 2.4 mg). Patients select a dose and inject. The pen mechanism controls injection depth and volume.
Compounded semaglutide is typically supplied in multi-dose vials. Patients must draw the correct volume using an insulin syringe, calculate the dose based on the concentration of the specific compounded product, and inject manually. This introduces opportunities for dosing errors that do not exist with prefilled pens. A patient switching between compounding pharmacies may encounter different concentrations, requiring recalculation. For an overview of comparative costs across all GLP-1 delivery formats, see our article on how much GLP-1 drugs actually cost.
The Regulatory Timeline
The regulatory status of compounded semaglutide has shifted rapidly.
2022-2024: Shortage era. The FDA listed semaglutide on its drug shortage list, which triggered a legal exception allowing compounding pharmacies to produce versions of the drug. Demand for GLP-1 drugs exceeded Novo Nordisk's manufacturing capacity, and compounded alternatives filled the gap. An estimated 3-5 million Americans used compounded semaglutide during this period.
February 21, 2025: Shortage resolved. The FDA determined that Novo Nordisk's supply met current and projected demand and removed semaglutide from the shortage list. This ended the legal basis for most compounding.
April-May 2025: Compounding deadlines. The FDA set wind-down periods: 503A pharmacies could continue compounding until April 22, 2025; 503B outsourcing facilities until May 22, 2025.
February 24, 2025: Legal challenge. The Outsourcing Facilities Association filed a lawsuit against the FDA, arguing the shortage resolution was arbitrary and that supply data did not support the determination. As of early 2026, this litigation continues to create regulatory uncertainty.
2026: Current status. Compounding of semaglutide at commercially available doses is restricted. Compounding pharmacies may still produce semaglutide at non-standard doses if a prescriber documents a specific clinical need not met by commercial products. The practical availability of compounded semaglutide has decreased but not been eliminated entirely. For background on the shortage itself, see our article on the GLP-1 shortage explained.
The Cost Equation
Cost is the primary driver of compounded semaglutide demand.
Wegovy's list price is approximately $1,349 per month. With insurance coverage (when available), patient costs range from $0-$500/month depending on plan design. Without insurance, the full list price applies, though Novo Nordisk offers a savings program capping costs at $500/month for eligible patients.
Compounded semaglutide has been available at $200-500/month from various telehealth platforms and compounding pharmacies, representing a 60-85% cost reduction. This price differential drove massive adoption, particularly among patients without insurance coverage for weight management medications. For more on the insurance landscape, see our article on GLP-1 insurance coverage challenges.
The cost comparison, however, omits several factors. Brand Wegovy includes the cost of the delivery device, cGMP manufacturing, adverse event monitoring, post-market safety surveillance, and the clinical trial investment that demonstrated efficacy. Compounded semaglutide externalizes these costs: patients bear the risk of untested products, and the healthcare system bears the cost of any adverse events. For the broader health economics perspective, our GLP-1 cost-effectiveness analysis examines whether GLP-1 drugs, at any price point, represent good value.
Safety Considerations
The FDA has issued multiple safety communications about compounded semaglutide.
Dosing errors. Because compounded semaglutide comes in vials requiring manual dose drawing, and because the concentration varies between compounders, dosing errors have been reported. Overdosing a GLP-1 agonist can cause severe nausea, vomiting, and pancreatitis.
Contamination risk. Multi-dose vials that are repeatedly punctured carry a higher contamination risk than single-use prefilled pens. Compounding pharmacies without rigorous sterility testing may produce products with bacterial or particulate contamination.
Salt form uncertainty. The FDA has specifically warned that semaglutide acetate and semaglutide sodium have not been evaluated for safety and should not be assumed equivalent to semaglutide base. The pharmacokinetic profile, including absorption rate, peak concentration, and duration of action, may differ.
No adverse event reporting. 503A compounding pharmacies are not required to report adverse events to the FDA. This means safety signals from compounded semaglutide may go undetected at the population level. A broader review of this regulatory gap for compounded peptides of all types is available in our article on compounded peptide safety monitoring.
The clinical safety profile of brand semaglutide is well-characterized. A comparative review of once-weekly GLP-1 receptor agonists found semaglutide's side effects (primarily gastrointestinal: nausea, vomiting, diarrhea) are predictable, dose-related, and generally manageable with proper titration.[5] Clinical practice guidance for semaglutide emphasizes the importance of the graduated dose-escalation protocol (starting at 0.25 mg and increasing monthly) to minimize gastrointestinal side effects.[6]
What This Means in Practice
The compounded semaglutide landscape has changed fundamentally since the shortage ended. Patients currently using compounded versions face a transition decision. The key considerations:
If transitioning to brand Wegovy: the dose-escalation schedule should be restarted or adjusted based on the compounded dose previously used. Direct conversion is complicated by the salt form difference, which means the actual semaglutide content of a compounded dose may differ from the nominal dose.
If continuing compounded: availability is restricted to non-standard doses with documented clinical need. The regulatory and legal landscape remains in flux, and continued access is not guaranteed.
Cost-of-control analysis: a 2020 economic analysis found that oral semaglutide (brand) was cost-effective compared to most injectable GLP-1 receptor agonists when considering the combined endpoints of HbA1c and weight targets achieved.[7] No equivalent economic analysis exists for compounded semaglutide, which makes cost comparisons incomplete.
The Bottom Line
Compounded semaglutide and brand Wegovy contain versions of the same active peptide but differ in salt form, manufacturing standards, quality testing, delivery device, clinical evidence, and regulatory status. Wegovy's clinical program encompassing over 15,000 patients across the SUSTAIN and STEP trials established its safety, efficacy, and cardiovascular benefit profile. Compounded semaglutide has no published clinical trial data. The cost differential (approximately 60-85% lower for compounded) drove widespread adoption during the 2022-2024 shortage, but the FDA's February 2025 shortage resolution has restricted compounding access. The two products should not be considered interchangeable.